Metraipolis › archive › dc_bb3b495674b0

Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial — Europe PMC PMID:41632146

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41632146
DOI
10.1001/jamanetworkopen.2025.49109
License (as archived)
solo-consultazione
Archived
2026-11-08T01:09:45.685Z
SHA-256 of the archived text
bbaa1aa7927447ee4d92efc13c3d73cbbfb769b986467c0b4d93ecd042d3a673
Stable URL of this page
https://metraipolis.com/documento/dc_bb3b495674b0

How to cite

Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial — Europe PMC PMID:41632146 — Europe PMC (en), https://europepmc.org/article/MED/41632146 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bb3b495674b0 (Metraipolis archive dc_bb3b495674b0, sha256 bbaa1aa7927447ee4d92efc13c3d73cbbfb769b986467c0b4d93ecd042d3a673)
BibTeX
@misc{dcbb3b495674b0,
  title = {Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial — Europe PMC PMID:41632146},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41632146},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bb3b495674b0; sha256 bbaa1aa7927447ee4d92efc13c3d73cbbfb769b986467c0b4d93ecd042d3a673},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41632146. Agents can read the archived copy with the MCP tool read_document.